CIRIUM
18.5.2022 13:32:08 CEST | Business Wire | Press release
Cirium , the aviation analytics company, and travel data analytics firm, 3Victors today announced a reseller partnership to enable Cirium to bring together flight schedules and passenger traffic data with online search data to interpret, understand and forecast passenger demand for airports and DMOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005656/en/
“Cirium and 3Victors share the mission to revolutionize the way the travel industry forecasts future demand,” said Kim Gesch, VP Airline Planning at Cirium. “Airlines and airports worldwide have long used the Diio by Cirium suite of products for network and traffic analysis. We have invested in the products and have enhanced the quality of our schedules, traffic, and fares data to ensure we maintain our leading position in the market.”
Chris Zando, CEO at 3Victors said: “Both 3Victors and Cirium are focused on high quality data science to bring real-time insights to commercial decision-making for the industry. The combination of both our capabilities provides the most dynamic forecasting in the market and at a time when it is most needed.”
Travel demand models have traditionally been built by comparing current bookings for flights against historical trends. Ticket prices were raised and lowered based on indicators from these models to ensure a flight was booked at optimum fare levels. Post-pandemic, changes to traveler booking behavior means past booking patterns may no longer be reliable as a guide to future demand.
Cirium and 3Victors will join forces to offer the most complete solution for analyzing future traffic, monitoring trends across time and detecting emerging opportunities. The offering will include the Diio by Cirium flight schedules, traffic and fares data alongside 3Victors DemandView search data, providing the most accurate forecast as possible.
This is particularly important for airports seeking better insights to retain and gain air service or DMOs wanting to optimize their marketing campaigns and traveler conversion rates.
3Victors’ search data is captured from more than half a million global touchpoints, including when a prospective traveler visits traditional or online travel agency, meta search, or travel search engine: or searches for flights. The most advanced data science is applied to interpret the traveler behavior, which provides a clear demand signal for flight bookings.
An example using 3Victors data shows that on a recent date there were large spikes in domestic demand originating in the UK and US, along with output showing year-over-year variation. If historical trends alone were used to forecast travel demand, the spikes in travel being seen in 2022 to date would not have been forecast.
Said Cirium’s Gesch: “Pairing Cirium’s capabilities with 3Victors’ contemporary travel demand insights means we can offer clients worldwide the most advanced solution to determine accurate traveler intent, monitor passenger trends, and identify correlations between what travelers are searching and actually booking.”
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com
About 3Victors
3Victors has built the industry’s first travel data analytics as a service platform in the Cloud. 3V’s proprietary 360° view of the travel landscape is the nexus between data volume, variety and velocity. 3V delivers market-leading data coverage and real-time analytics and insights, empowering companies with actionable intelligence.
For further information please follow 3Victors on LinkedIn or visit https://www.3victors.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005656/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom